Fig. 3. (A) Original graphs from Bhasin et al. [25] show increase in change in prostate-specific antigen (PSA) with higher serum testosterone doses. These patients were maintained on gonadotropin releasing hormone agonists while treated with IM testosterone enanthate injections. While only injection doses of 300 mg were shown to have statistically significant changes compared to 25 mg injections (p<0.05), it must be kept in mind that these are different patients measured at the same time point on different doses. Further maintenance of doses beyond 20 weeks of treatment, or even long term follow-up is not presented here. (B) Despite the drastically different scales of means and variances presented by serum testosterone and PSA, and despite the original authors having presented graphs in their original paper, Morgentaler and Traish [1] reconstructed these measurements on questionable scales. ^*p<0.0001. Original graph from Bhasin et al. J Clin Endocrinol Metab 2005;90:678-88 [25], with permission of Oxford University Press. Original graph from Morgentaler and Traish. Eur Urol 2009;55:310–20 [1], with permission of Elsevier.